Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT)

23/10/2025
09/04/2026
EU PAS number:
EUPAS1000000789
Study
Finalised
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000000789

Study ID

1000000789

Official title and acronym

Assessing the impact of remission at 12-months post-initiation of biologic therapy on long-term clinical outcomes of patients with severe asthma (SPOTLIGHT)

DARWIN EU® study

No

Study countries

Argentina
Belgium
Brazil
Bulgaria
Canada
Colombia
Denmark
Estonia
Greece
India
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Mexico
Norway
Poland
Portugal
Saudi Arabia
Singapore
Spain
Taiwan
United Arab Emirates
United Kingdom
United States

Study description

Description of remission patterns and an assessment of the long-term impact of remission in patients with severe asthma

Study status

Finalised
Research institutions and networks

Institutions

Networks

International Severe Asthma Registry

Contact details

David Price 0000-0002-9728-9992

Primary lead investigator
ORCID number:
0000-0002-9728-9992

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pharmaceutical companies: AstraZeneca
Other: Optimum Patient Care Global
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable